Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetic study Clear all
Completed Phase 2 Interventional Results available

A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream

NCT03462927
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
MC2-01 Cream, CAL/BDP combination
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Sweetwater, Florida
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Results available

Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

NCT04370873
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Frespaciguat, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Lexington, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 19, 2026, 6:36 AM EDT
Terminated Phase 1 Interventional Results available

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

NCT02784795
View directory record Official record
Conditions
Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma
Interventions
LY3039478, Taladegib, Abemaciclib, Cisplatin, Gemcitabine, Carboplatin, LY3023414
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Miami, Florida • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 19, 2026, 6:36 AM EDT
Terminated Phase 1 Interventional

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

NCT00112619
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Results available

Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

NCT00617994
View directory record Official record
Conditions
Psoriasis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Fridley, Minnesota • Rochester, New York • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

NCT01462851
View directory record Official record
Conditions
Healthy
Interventions
PF-05297909 25 mg, PF-05297909 100 mg, PF-05297909 250 mg, PF-05297909 525 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The O'Neil Long Acting Naltrexone Implant (OLANI) Pharmacokinetic (PK)/Safety Study in Healthy Volunteers

NCT03810495
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
naltrexone implant
Drug
Lead sponsor
Go Medical Industries Pty Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease

NCT05174039
View directory record Official record
Conditions
Batten Disease
Interventions
Miglustat 100 milligrams (mg) Oral Capsule
Drug
Lead sponsor
Beyond Batten Disease Foundation
Other
Eligibility
17 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use

NCT01631383
View directory record Official record
Conditions
Cocaine Use
Interventions
l-THP (l-tetrahydropalmatine), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1 Interventional

AMG 386 Drug-Drug Interaction Study With Paclitaxel

NCT01992341
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
AMG 386, Paclitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Aurora, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Not applicable Interventional Results available

PK/PD Pediatric ADHD Classroom Study

NCT02536105
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate HCl ER tablets 1, Placebo, Methylphenidate HCl ER tablets 2, Methylphenidate HCl ER for suspension
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

NCT00619619
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Little Rock, Arkansas • North Miami, Florida • Terre Haute, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

NCT02053792
View directory record Official record
Conditions
Hemophilia B
Interventions
rIX-FP
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Up to 70 Years · Male only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Aurora, Colorado • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects

NCT00914511
View directory record Official record
Conditions
Avanfil ADME, Semen Exposure, Sperm Function
Interventions
avanafil 200mg
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Formulations of LY3074828 in Healthy Participants

NCT03662100
View directory record Official record
Conditions
Healthy
Interventions
LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS)
Biological · Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

NCT02536911
View directory record Official record
Conditions
Gaucher Disease
Interventions
eliglustat
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic (PK) Study of NatrOVA Topical Creme (1%) in Pediatric Subjects 6 to 24 Months of Age

NCT00410709
View directory record Official record
Conditions
Pediculosis Capitis (Head Lice)
Interventions
NatrOVA Creme Rinse (1%)
Drug
Lead sponsor
ParaPRO LLC
Industry
Eligibility
6 Months to 24 Months
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2008 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions

NCT01330199
View directory record Official record
Conditions
Healthy Adult Females
Interventions
Pharmacokinetic Sampling
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 19, 2026, 6:36 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment

NCT06740799
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Quizartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Miami, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 2 Interventional

Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia

NCT01052987
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Tranilast, Allopurinol, Combination - Tranilast and Allopurinol, 400 mg Allopurinol, High dose combination
Drug
Lead sponsor
Nuon Therapeutics, Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Honolulu, Hawaii • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

NCT02224053
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

NCT05819775
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
CSL312
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years to 11 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 19, 2026, 6:36 AM EDT
Completed Phase 1 Interventional

PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias

NCT01169012
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia
Interventions
Clofarabine
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 19, 2026, 6:36 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Investigations of Fetal Anesthesia During Maternal Fetal Surgery

NCT07571811
View directory record Official record
Conditions
Fetal Anesthesia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 19, 2026, 6:36 AM EDT